TransCode Therapeutics (NASDAQ: RNAZ), a clinical-stage company focused on developing RNA-based therapeutics for high-risk and advanced cancers, has announced the publication of a peer-reviewed article in the journal Cancers detailing preclinical results for its lead candidate, TTX-MC138, in a model of breast cancer bone metastasis. The findings represent a significant step forward in the company's mission to address metastatic disease, which is responsible for the majority of cancer-related deaths.
The study demonstrated that TTX-MC138, when administered systemically, successfully accumulated in metastatic bone lesions. Once there, it reduced the expression of microRNA-10b (miR-10b), a known promoter of metastasis, and subsequently increased the expression of HOXD10, a downstream tumor-suppressor gene. This molecular mechanism translated into a significant survival benefit for treated subjects compared to controls. Furthermore, the treatment was well tolerated, with no observed systemic toxicity, suggesting a favorable safety profile that could be crucial for clinical translation.
These results are particularly noteworthy because bone metastasis is a common and debilitating complication of advanced breast cancer, often leading to pain, fractures, and other serious clinical events. Current treatment options are largely palliative, underscoring the urgent need for therapies that specifically target the metastatic process. TTX-MC138's ability to home to metastatic lesions and inhibit a key driver of metastasis offers a novel approach that could potentially alter the disease trajectory.
TransCode's proprietary oligonucleotide nanotechnology platform enables the targeted delivery of therapeutic agents to metastatic sites, a critical advantage given the difficulty of treating disseminated disease. The company's lead candidate, TTX-MC138, is designed to inhibit miR-10b, a well-documented biomarker of metastasis that is overexpressed in a variety of aggressive tumors. By silencing this microRNA, TTX-MC138 aims to disrupt the metastatic cascade, potentially preventing the spread of cancer and improving patient outcomes.
The implications of this research extend beyond breast cancer. The study's authors suggest that the approach may be applicable to other metastatic disease settings, given the prevalence of miR-10b overexpression in multiple cancer types. This broad potential makes TTX-MC138 a promising candidate not only for breast cancer but also for other solid tumors where metastasis is a major challenge.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. In addition to TTX-MC138, the company has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system to recognize and destroy cancer cells. The positive preclinical data for TTX-MC138 adds to a growing body of evidence supporting the company's innovative approach.
Investors and stakeholders can access the full press release and additional information through the company's newsroom at https://ibn.fm/RNAZ. For more details on the study, the full press release is available at https://ibn.fm/E6gbq.
